Looking into the future of fluorescence-guided tumor removal

A recent article from Forbes examined the potential future of using fluorescence detection for tumor removal.

Fluorescence detection, in theory, could help surgeons see where a tumor ends and where healthy tissue begins.

Forbes broke down how the process could work in a clinical setting: “A breast cancer patient is connected to an IV that sends dye molecules into the bloodstream that travel to the site of the patient’ tumor or tumors. Then, the surgeon inserts a tiny camera into the patient’s chest so the tissue can be observed on a nearby monitor. The light that these optical probes emit can be picked up by a special camera that can see light that penetrates through skin and tissues. On the screen, the cancer cells glow a bright green color to help guide the surgeon to the tumor site.”

Fluorescence detection with non-targeted dye is already commonly used to find blood vessels, but recent scientific developments have increased the likelihood of light-guided tumor removal.

Click the link below to view the full story from Forbes:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.